Dear Editor,

Much of what we know about atopic dermatitis (AD) pathogenesis revolves around the fundamental concepts of barrier dysfunction, pruritus/inflammation, and a dysfunctional immune response. Dermatologists often give advice concentrating on moisturizing, bathing, cleansing, and reducing symptoms of itching and dryness for patients with AD. A recent observation in AD research is that oxidative stress plays a central role in the pathogenesis of this chronic relapsing skin disorder. Events that lead to skin barrier defects have also been correlated with the release of reactive oxygen species, which directly damage the skin's cellular components, such as the cell membrane, organelles, and even DNA (Fig. 1; Ji and Li, 2016).

Oxidative stress is recognized as having an impact on hypertension, diabetes, heart disease, and certain cancers, as well as skin disorders. Studies have highlighted oxidative stress and the effects of antioxidant therapy on skin diseases (Fig. 2). For certain skin diseases (e.g., AD), higher levels of oxidative damage markers are seen during exacerbations (Baek and Lee, 2016). Also, at least one of the following defects can be found in patients with AD: Oxidative stress, increased oxidative stress signals during flares, and/or decreased antioxidant levels (Ji and Li, 2016). Patients with AD often have lower systemic antioxidant levels and may have lower dietary intake of nutrients with antioxidant properties, but the relationship between systemic antioxidant status and AD risk warrants further evaluation in large, prospective studies.

Standard moisturizer therapy with emollients has been the therapy of choice for barrier repair. Growing evidence shows that topical antioxidants could provide additional protection against oxidative stress when admixed with moisturizers. Barrier-enhancing moisturizers in combination with antioxidants were observed to have comparable effects as topical corticosteroids on the permeability of the skin barrier (Man et al., 2015).

Recently, a review of the antioxidant furfuryl palmitate and its effect on mild-to-moderate AD and other related skin disorders (i.e., atopic, seborrheic, irritative, allergic contact dermatitis, xerosis, and cutaneous inflammatory pathologies) has been published.

In conclusion, oxidative stress may be another potential target in AD management. Alternative pharmaceutical antioxidant agents, such as furfuryl palmitate and its derivatives, may provide effective and safe steroid-sparing options for AD in the future. More robust trials are needed to show the definitive effects of these agents on the prevention and treatment of AD exacerbations.

Conflict of Interest

None.

Fig. 1. Interplay among oxidative stress, skin barrier defect, and inflammation in atopic dermatitis.

Furfuryl palmitate and its derivatives were effective and safe in treating AD, may be used as an adjunct to moisturizers, and may even be considered as a replacement for topical corticosteroids and calcineurin inhibitors (Table 1; Pigatto and Diani, 2018).

In conclusion, oxidative stress may be another potential target in AD management. Alternative pharmaceutical antioxidant agents, such as furfuryl palmitate and its derivatives, may provide effective and safe steroid-sparing options for AD in the future. More robust trials are needed to show the definitive effects of these agents on the prevention and treatment of AD exacerbations.

Conflict of Interest

None.
I would like to thank Relife s.r.l for the unrestricted educational grant provided for this research.

The author(s) confirm that any aspect of the work covered in this manuscript that has involved human patients has been conducted with the ethical approval of all relevant bodies.

The author thanks Dr. Dennis Malvin H. Malgapo of MIMS Pte Ltd for his medical writing services.

**Funding**

I would like to thank Relife s.r.l for the unrestricted educational grant provided for this research.

**Study Approval**

The author(s) confirm that any aspect of the work covered in this manuscript that has involved human patients has been conducted with the ethical approval of all relevant bodies.

**Acknowledgments**

The author thanks Dr. Dennis Malvin H. Malgapo of MIMS Pte Ltd for his medical writing services.
childhood atopic dermatitis associated with pityriasis alba. A double-blind, placebo-controlled clinical trial. G Ital Dermatol Venereol. 2012 Dec; 147 (6 Suppl 1):1–8.

Pigatto P, Lauriola M, Vaccari G. A single-center, randomized, double-blind, perspective, controlled study of efficacy and safety of a furfuryl-containing cream versus vehicle in the treatment of 40 adult patients with mild to moderate atopic dermatitis. In: Poster session 20th EADV Congress. Lisbon, Portugal; 2011.

Pigatto PD, Diani M. Beneficial effects of antioxidant furfuryl palmitate in non-pharmacologic treatments (prescription emollient devices, PEDs) for atopic dermatitis and related skin disorders. Dermatol Ther (Heidelb) 2018;8 (3):339–47.

Tripodi S, Di Rienzo Businco A, Panetta V, Pingitore G, Volterrani A, Frediani T, et al. Lack of efficacy of topical furfuryl palmitate in pediatric atopic dermatitis: a randomized double-blind study. J Investig Allergol Clin Immunol 2009;19 (3):204–9.